Centessa Pharmaceuticals Ownership | Who Owns Centessa Pharmaceuticals?


OverviewForecastRevenueFinancialsChart

Centessa Pharmaceuticals Ownership Summary


Centessa Pharmaceuticals is owned by 93.39% institutional investors, 1.36% insiders, and 5.25% retail investors. Medicxi ventures management (jersey) is the largest institutional shareholder, holding 17.17% of CNTA shares. T. Rowe Price Health Sciences is the top mutual fund, with 2.64% of its assets in Centessa Pharmaceuticals shares.

CNTA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockCentessa Pharmaceuticals93.39%1.36%5.25%
SectorHealthcare Stocks 88.01%8.90%3.09%
IndustryBiotech Stocks 109.70%8.77%-18.47%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Medicxi ventures management (jersey)19.96M17.17%$334.38M
General atlantic9.68M9.69%$87.43M
Ecor1 capital5.71M5.72%$51.60M
First light asset management4.78M4.79%$43.17M
Perceptive advisors3.93M3.94%$35.52M
Price t rowe associates inc /md/3.53M3.53%$31.88M
Vida ventures advisors3.93M3.38%$65.86M
Adage capital partners gp3.13M3.13%$28.22M
Tcg crossover management2.89M2.89%$26.10M
Fmr2.79M2.79%$25.17M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Medicxi ventures management (jersey)19.96M63.20%$334.38M
Vida ventures advisors3.93M45.01%$65.86M
First light asset management4.78M3.78%$43.17M
Octagon capital advisors lp2.35M3.33%$21.18M
General atlantic9.68M2.75%$87.43M
Tcg crossover management2.89M2.72%$26.10M
5am venture management1.25M2.51%$11.24M
Exome asset management274.90K2.21%$2.48M
Ecor1 capital5.71M1.58%$51.60M
Tanager wealth management llp696.10K1.51%$11.66M

Top Buyers

HolderShares% AssetsChange
First light asset management4.78M3.78%1.78M
Farallon capital management2.00M0.09%1.63M
Cormorant asset management, lp1.61M0.84%1.05M
Driehaus capital management2.09M0.18%988.00K
Adage capital partners gp3.13M0.05%875.00K

Top Sellers

HolderShares% AssetsChange
Point72 asset management1.76M0.04%-495.71K
Millennium management49.48K0.00%-237.91K
Ensign peak advisors---125.16K
Landscape capital management---90.24K
Exoduspoint capital management, lp---87.21K

New Positions

HolderShares% AssetsChangeValue
T. rowe price investment management833.99K0.00%833.99K$7.53M
Baker bros. advisors lp549.21K0.06%549.21K$4.96M
Nantahala capital management450.00K0.24%450.00K$4.06M
Dafna capital management122.88K0.27%122.88K$1.11M
Monashee investment management103.19K0.12%103.19K$931.82K

Sold Out

HolderChange
Spire wealth management-70.00
Nbc securities-138.00
Advisor group-407.00
Golden state equity partners-1.70K
State of tennessee, treasury department-5.80K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202410629.27%108,573,10325.51%931.50%7672.73%16-15.79%
Jun 30, 20248114.08%86,506,23316.28%861.45%44-6.38%18260.00%
Mar 31, 20247116.39%74,395,2734.37%771.42%4756.67%5-54.55%
Dec 31, 20236122.00%71,280,100-1.79%731.27%3036.36%1110.00%
Sep 30, 2023508.70%72,578,6363.18%761.39%2215.79%1042.86%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
T. Rowe Price Health Sciences3.48M2.64%314.52K
Fidelity Select Biotechnology2.98M2.26%-
Franklin Biotechnology Discv A(acc)USD1.18M0.89%-
American Century Small Cap Growth Inv854.44K0.65%-146.17K
American Century U.S. Small Cap Growth854.44K0.65%-146.17K
T. Rowe Price US Small-Cap Core Equity845.34K0.64%-48.37K
T. Rowe Price Small-Cap Stock845.34K0.64%-46.43K
Franklin Biotechnology Discovery A678.97K0.52%-
T. Rowe Price Small-Cap Value657.17K0.50%-
T. Rowe Price New Horizons644.64K0.49%-

Recent Insider Transactions


DateNameRoleActivityValue
Jan 27, 2025Weinhoff Gregory M Chief Business OfficerSell$193.43K
Jan 21, 2025SAHA SAURABH Chief Executive OfficerSell$841.12K
Jan 21, 2025SAHA SAURABH Chief Executive OfficerSell$26.31K
Jan 15, 2025HUSSAIN IQBAL J General CounselSell$91.74K
Dec 26, 2024Weinhoff Gregory M Chief Business OfficerSell$170.40K

Insider Transactions Trends


DateBuySell
2024 Q4-18
2024 Q3-11
2024 Q2--
2024 Q1-3
2023 Q4--

CNTA Ownership FAQ


Who Owns Centessa Pharmaceuticals?

Centessa Pharmaceuticals shareholders are primarily institutional investors at 93.39%, followed by 1.36% insiders and 5.25% retail investors. The average institutional ownership in Centessa Pharmaceuticals's industry, Biotech Stocks , is 109.70%, which Centessa Pharmaceuticals falls below.

Who owns the most shares of Centessa Pharmaceuticals?

Centessa Pharmaceuticals’s largest shareholders are Medicxi ventures management (jersey) (19.96M shares, 17.17%), General atlantic (9.68M shares, 9.69%), and Ecor1 capital (5.71M shares, 5.72%). Together, they hold 32.59% of Centessa Pharmaceuticals’s total shares outstanding.

Does Blackrock own Centessa Pharmaceuticals?

BlackRock is not among the top 10 institutional shareholders of Centessa Pharmaceuticals.

Who is Centessa Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Medicxi ventures management (jersey) is Centessa Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 63.20% of its assets in 19.96M Centessa Pharmaceuticals shares, valued at 334.38M$.

Who is the top mutual fund holder of Centessa Pharmaceuticals shares?

T. Rowe Price Health Sciences is the top mutual fund holder of Centessa Pharmaceuticals shares, with 2.64% of its total shares outstanding invested in 3.48M Centessa Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools